SPARCL1 and hilar cholangiocarcinoma: As reported, Loss of SPARCL1 was more observed in N1/2-stage and high/moderate-differentiated tumors than in N0-stage and poor/un-differentiated hilar cholangiocarcinoma, respectively [28].